Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
protein_peptide
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
56High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00089063CT.gov Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma | — | Completed | — | — | — |
NCT00085189CT.gov Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma | — | Completed | — | — | — |
NCT01989572CT.gov Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Iris Melanoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tyrosinase Peptide (this asset) | National Cancer Institute (NCI) | P3 | BB · 69 |
| Sargramostim | National Cancer Institute (NCI) | P3 | BB |
| Cyclophosphamide | H. Lee Moffitt Cancer Center and Research Institute | P2 | B |
| Carboplatin | National Cancer Institute (NCI) | P2 | B |
| gp100 antigen | National Cancer Institute (NCI) | P2 | B |
| Ifa | National Cancer Institute (NCI) | P2 | B |
| Dacarbazine | National Cancer Institute (NCI) | P2 | B |
| Montanide Isa 51 | National Cancer Institute (NCI) | P2 | B |
| Cediranib | National Cancer Institute (NCI) | P2 | B |
+15 more in the Iris Melanoma cohort
Other indications for Tyrosinase Peptide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cutaneous Melanoma | — | P3 | BBB · 72 |
| Uveal Melanoma | — | P3 | BB · 71 |
| Melanoma | — | P3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tyrosinase Peptide in Iris Melanoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tyrosinase-peptide-iris-melanoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →